Adherence to preventive measures after SARS-CoV-2 vaccination and after awareness of antibody response in kidney transplant recipients in the Netherlands : a nationwide questionnaire study
© 2023 The Author(s)..
Background: Kidney transplant recipients (KTRs) were advised to tightly adhere to government recommendations to curb the spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) because of a high risk of morbidity and mortality and decreased immunogenicity after vaccination. The aim of this study was to analyse the change in adherence to preventive measures after vaccination and awareness of antibody response, and to evaluate its effectiveness.
Methods: In this large-scale, national questionnaire study, questionnaires were sent to 3531 KTRs enrolled in the Dutch RECOVAC studies, retrospectively asking for adherence to nine preventive measures on a 5-point Likert scale before and after SARS-CoV-2 vaccination and after awareness of antibody response. Blood samples were collected 28 days after the second vaccination. Antibody response was categorised as non-responder (≤50 BAU/mL), low-responder (>50 ≤ 300 BAU/mL) or high-responder (>300 BAU/mL), and shared with participants as a correlate of protection. Participants of whom demographics on sex and age, blood samples and completed questionnaires were available, were included. Our study took place between February 2021 and January 2022. The primary outcome of adherence before and after vaccination was assessed between August and October 2021 and compared via the Wilcoxon signed rank sum test. Logistic regression analysis was performed to estimate the association between antibody response and non-adherence, and adherence on acquiring SARS-CoV-2 infection. This study is registered at ClinicalTrials.gov (NCT04841785).
Findings: In 2939 KTRs (83%) who completed the first questionnaire on adherence to preventive measures, adherence was higher before than after vaccination (4.56, IQR 4.11-4.78 and 4.22, IQR 3.67-4.67, p < 0.001). Adherence after awareness of antibody response was analysed in 2399 KTRs (82%) of whom also blood samples were available, containing 949 non-responders, 500 low-responders and 950 high-responders. Compared to non-responders, low- and high-responders reported higher non-adherence. Higher adherence was associated with lower infection rates before and after vaccination (OR 0.67 [0.51-0.91], p = 0.008 and OR 0.48 [0.28-0.86], p = 0.010).
Interpretation: Adherence decreased after SARS-CoV-2 vaccination and in KTRs who were aware of a subsequent antibody response compared with those without. Preventive measures in this vulnerable group seem to be effective, regardless of vaccination status. This study starts a debate on sharing antibody results with the patient and future studies should elucidate whether decreased adherence in antibody responders is justified, also in view of future pandemics.
Funding: The Netherlands Organization for Health Research and Development and the Dutch Kidney Foundation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
EClinicalMedicine - 62(2023) vom: 03. Aug., Seite 102103 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Frölke, Sophie C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adherence |
|---|
| Anmerkungen: |
Date Revised 04.08.2023 published: Electronic-eCollection ClinicalTrials.gov: NCT04841785 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.eclinm.2023.102103 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360331653 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360331653 | ||
| 003 | DE-627 | ||
| 005 | 20231226082806.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eclinm.2023.102103 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360331653 | ||
| 035 | |a (NLM)37533418 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Frölke, Sophie C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adherence to preventive measures after SARS-CoV-2 vaccination and after awareness of antibody response in kidney transplant recipients in the Netherlands |b a nationwide questionnaire study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.08.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ClinicalTrials.gov: NCT04841785 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Author(s). | ||
| 520 | |a Background: Kidney transplant recipients (KTRs) were advised to tightly adhere to government recommendations to curb the spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) because of a high risk of morbidity and mortality and decreased immunogenicity after vaccination. The aim of this study was to analyse the change in adherence to preventive measures after vaccination and awareness of antibody response, and to evaluate its effectiveness | ||
| 520 | |a Methods: In this large-scale, national questionnaire study, questionnaires were sent to 3531 KTRs enrolled in the Dutch RECOVAC studies, retrospectively asking for adherence to nine preventive measures on a 5-point Likert scale before and after SARS-CoV-2 vaccination and after awareness of antibody response. Blood samples were collected 28 days after the second vaccination. Antibody response was categorised as non-responder (≤50 BAU/mL), low-responder (>50 ≤ 300 BAU/mL) or high-responder (>300 BAU/mL), and shared with participants as a correlate of protection. Participants of whom demographics on sex and age, blood samples and completed questionnaires were available, were included. Our study took place between February 2021 and January 2022. The primary outcome of adherence before and after vaccination was assessed between August and October 2021 and compared via the Wilcoxon signed rank sum test. Logistic regression analysis was performed to estimate the association between antibody response and non-adherence, and adherence on acquiring SARS-CoV-2 infection. This study is registered at ClinicalTrials.gov (NCT04841785) | ||
| 520 | |a Findings: In 2939 KTRs (83%) who completed the first questionnaire on adherence to preventive measures, adherence was higher before than after vaccination (4.56, IQR 4.11-4.78 and 4.22, IQR 3.67-4.67, p < 0.001). Adherence after awareness of antibody response was analysed in 2399 KTRs (82%) of whom also blood samples were available, containing 949 non-responders, 500 low-responders and 950 high-responders. Compared to non-responders, low- and high-responders reported higher non-adherence. Higher adherence was associated with lower infection rates before and after vaccination (OR 0.67 [0.51-0.91], p = 0.008 and OR 0.48 [0.28-0.86], p = 0.010) | ||
| 520 | |a Interpretation: Adherence decreased after SARS-CoV-2 vaccination and in KTRs who were aware of a subsequent antibody response compared with those without. Preventive measures in this vulnerable group seem to be effective, regardless of vaccination status. This study starts a debate on sharing antibody results with the patient and future studies should elucidate whether decreased adherence in antibody responders is justified, also in view of future pandemics | ||
| 520 | |a Funding: The Netherlands Organization for Health Research and Development and the Dutch Kidney Foundation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adherence | |
| 650 | 4 | |a Behavior | |
| 650 | 4 | |a Kidney transplantation | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccination | |
| 700 | 1 | |a Bouwmans, Pim |e verfasserin |4 aut | |
| 700 | 1 | |a Messchendorp, A Lianne |e verfasserin |4 aut | |
| 700 | 1 | |a Vervoort, Johanna P M |e verfasserin |4 aut | |
| 700 | 1 | |a Abrahams, Alferso C |e verfasserin |4 aut | |
| 700 | 1 | |a de Vries, Aiko P J |e verfasserin |4 aut | |
| 700 | 1 | |a Nieuwkerk, Pythia T |e verfasserin |4 aut | |
| 700 | 1 | |a Hemmelder, Marc H |e verfasserin |4 aut | |
| 700 | 1 | |a Gansevoort, Ron T |e verfasserin |4 aut | |
| 700 | 1 | |a Hilbrands, Luuk B |e verfasserin |4 aut | |
| 700 | 1 | |a Reinders, Marlies E J |e verfasserin |4 aut | |
| 700 | 1 | |a Sanders, Jan-Stephan F |e verfasserin |4 aut | |
| 700 | 1 | |a Bemelman, Frederike J |e verfasserin |4 aut | |
| 700 | 1 | |a Geerlings, Suzanne E |e verfasserin |4 aut | |
| 700 | 0 | |a RECOVAC Collaborators |e verfasserin |4 aut | |
| 700 | 1 | |a Imhof, C |e investigator |4 oth | |
| 700 | 1 | |a Idzinga, C |e investigator |4 oth | |
| 700 | 1 | |a Siegert, C |e investigator |4 oth | |
| 700 | 1 | |a Baan, C C |e investigator |4 oth | |
| 700 | 1 | |a Konings, C J A M |e investigator |4 oth | |
| 700 | 1 | |a van Kessel, C |e investigator |4 oth | |
| 700 | 1 | |a van Baarle, D |e investigator |4 oth | |
| 700 | 1 | |a Diavatopoulos, D A |e investigator |4 oth | |
| 700 | 1 | |a Standaar, D |e investigator |4 oth | |
| 700 | 1 | |a Ten Hoope, E |e investigator |4 oth | |
| 700 | 1 | |a Til, E |e investigator |4 oth | |
| 700 | 1 | |a Remmerswaal, E B M |e investigator |4 oth | |
| 700 | 1 | |a van der Klis, F |e investigator |4 oth | |
| 700 | 1 | |a Fritsen, H R |e investigator |4 oth | |
| 700 | 1 | |a Stijnman, I |e investigator |4 oth | |
| 700 | 1 | |a Brinkman, J N |e investigator |4 oth | |
| 700 | 1 | |a Cheng, J |e investigator |4 oth | |
| 700 | 1 | |a den Biggelaar, L |e investigator |4 oth | |
| 700 | 1 | |a Ten Dam, M |e investigator |4 oth | |
| 700 | 1 | |a Steenhuis, M |e investigator |4 oth | |
| 700 | 1 | |a Zwerink, M |e investigator |4 oth | |
| 700 | 1 | |a Braks, M H J |e investigator |4 oth | |
| 700 | 1 | |a Willems, M |e investigator |4 oth | |
| 700 | 1 | |a Kho, M L |e investigator |4 oth | |
| 700 | 1 | |a Rots, N |e investigator |4 oth | |
| 700 | 1 | |a Vart, P |e investigator |4 oth | |
| 700 | 1 | |a van der Molen, R G |e investigator |4 oth | |
| 700 | 1 | |a van den Dorpel, R M A |e investigator |4 oth | |
| 700 | 1 | |a Malaha, R S R K |e investigator |4 oth | |
| 700 | 1 | |a Ter Meulen, R C G |e investigator |4 oth | |
| 700 | 1 | |a Rispens, T |e investigator |4 oth | |
| 700 | 1 | |a Steenvoorden, T |e investigator |4 oth | |
| 700 | 1 | |a de Ronde, T |e investigator |4 oth | |
| 700 | 1 | |a Peters, V J P |e investigator |4 oth | |
| 700 | 1 | |a Konijn, W S |e investigator |4 oth | |
| 700 | 1 | |a Janssen, W M T |e investigator |4 oth | |
| 700 | 1 | |a Bos, W J |e investigator |4 oth | |
| 700 | 1 | |a Adema, Y M R |e investigator |4 oth | |
| 700 | 1 | |a Vegting, Y |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t EClinicalMedicine |d 2018 |g 62(2023) vom: 03. Aug., Seite 102103 |w (DE-627)NLM289300495 |x 2589-5370 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g day:03 |g month:08 |g pages:102103 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eclinm.2023.102103 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |b 03 |c 08 |h 102103 | ||